November 2019 FAQs
- Update: What information has been yielded from the cardiovascular safety studies on new anti-hyperglycemic agents?
- What criteria exist to suggest use of denosumab for the treatment of hypercalcemia of malignancy over other calcium reducing options?
- What is the pharmaceutical contaminant N-nitrosodimethylamine (NDMA) and what risk does it pose to humans?